Abstract. The aim of the present study was to explore the effect of knocking down the expression of β-catenin by small interference (si)RNA on the activity of the Wnt/β-catenin signaling pathway, and the proliferation, apoptosis and invasion abilities of the human colon cancer cell line SW480. For that purpose, double-stranded siRNA targeting β-catenin (β-catenin-siRNA) was synthesized and transfected into SW480 cells. Reverse transcription-polymerase chain reaction (RT-PCR) and western blotting were used to detect the messenger (m)RNA and protein levels of β-catenin in SW480 cells. To detect cell proliferation, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was performed, while cell apoptosis and caspase-3 activity were detected by flow cytometry and caspase-3 activity assay, respectively. Matrigel invasion assay was performed to detect the influence of siRNA-mediated gene silencing on the invasion and metastasis of SW480 cells in vitro. The results of RT-PCR and western blot analysis demonstrated that, compared with the blank control, negative control and liposome groups, β-catenin-siRNA transfected SW480 cells had significantly decreased mRNA and protein levels of β-catenin. In addition, following β-catenin-siRNA transfection, the proliferation of SW480 cells was significantly lower than that of the blank control, negative control and liposome groups, while the apoptosis rate increased in β-catenin-siRNA transfected cells, compared with the aforementioned groups. Invasion assay showed that, following β-catenin-siRNA transfection, the number of SW480 cells infiltrating through the Matrigel membrane was significantly lower than that of the blank control, negative control and liposome groups. Following β-catenin-siRNA transfection, the caspase-3 activity in SW480 cells was lower than that in the blank control, negative control and liposome groups. These results indicate that siRNA-mediated silencing of β-catenin could inhibit the proliferation and invasion of SW480 cells and induce apoptosis, thus providing novel potential strategies for the clinical treatment of colon cancer, and may serve as a novel target for cancer therapy.
Introduction
The Wnt/β-catenin signaling pathway is important in embryogenesis and tumor development, and has been recognized as one of the key signaling pathways during tumorigenesis (1, 2) . The aberrant activation of the Wnt/β-catenin signaling pathway may increase cell proliferation, which results in the generation of abnormal proteins, thereby accelerating the formation of tumors and carcinogenesis through the expression of downstream target genes (3) . A previous study demonstrated that ~90% of cases of colon cancer were associated with excessive activation of this pathway (4) . β-catenin is the key molecule of the Wnt/β-catenin signaling pathway (5) . Thus, silencing the β-catenin gene may inhibit the development and invasion of colon cancer. However, data regarding how to influence colon cancer cells by silencing the β-catenin gene are limited. In the present study, the expression of the β-catenin gene in the Wnt/β-catenin signaling pathway was silenced by small interference (si)RNA to study its effect on colon cancer cell proliferation, apoptosis and invasion, and to explore the clinical value of blocking β-catenin gene expression as a therapeutic molecular target.
Materials and methods

Materials.
The human colon cancer cell line SW480 was purchased from the China Center for Type Culture Collection of Wuhan University (Wuhan, China). The liposomal transfection agent Lipofectamine ® 2000 was purchased from Invitrogen (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Reverse transcription-polymerase chain reaction (RT-PCR) kit was purchased from Fermentas (Thermo Fisher Scientific, Inc.). Matrigel was purchased from BD Biosciences (Franklin Lakes, NJ, USA), while Transwell chambers were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).
Synthesis of β-catenin-siRNA. siRNA targeting the β-catenin gene was synthesized by Shanghai GenePharma Co., Ltd. (Shanghai, China), and its sequence was: Sense, 5'-CAT GUG UTG GUA AGC UCUA-3' and anti-sense, 5'-GCA ACA GTT GCA GAG AGGU-3'. Upon synthesis, Basic Local Alignment Search Tool analysis was performed in GeneBank (blast.ncbi. nlm.nih.gov/Blast.cgi) excluding other homologous genes. The negative control siRNA used in the present study was purchased from Shanghai GenePharma, Co., Ltd., and the sequence was as follows: Sense, 5'-AUG CUG ATC AGU GUC GATU-3' and anti-sense, 5'-CAG AGA GCT CGU GAG AGTA-3'.
Transfection of the human colon cancer cell line SW480. SW480 cells were transfected with the Lipofectamine ® 2000 transfection reagent, according to the manufacturer's protocol. The human colon cancer cell line SW480 was conventionally cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum (FBS) (Shanghai Solarbio Bioscience & Technology Co., Ltd., Shanghai, China) at 37˚C in a 5% CO 2 humidified incubator. Cells in the logarithmic growth phase were selected for transfection. Samples were divided into the following four groups: i) Blank control group (non-transfected cells); ii) negative control group (cells transfected with negative control-siRNA); iii) liposome group (cells transfected only with the aforementioned liposomal transfection agent); and iv) transfected group (cells transfected with β-catenin-siRNA).
RT-PCR assay for the detection of siRNA efficiency on β-catenin gene expression. Total RNA was extracted using TRIzol (Shanghai GenePharma, Co., Ltd.), and next subjected to RT reaction. RT-PCR experiments were performed using the AccessQuick RT-PCR System (Promega Corporation, Madison, WI, USA) using 1 µg total RNA. The primers were purchased from Shanghai GenePharma, Co., Ltd. and the sequences were as follows: β-catenin, forward 5'-AAA GCG GCT GTT AGT CAC TGG-3' and reverse 5'-GAC TTG GGA GGT ATC CAC ATCC-3'; β-actin, forward 5'-GAA ATC GTG CGT GAC ATTA-3' and reverse 5'-ACT CAT CGT ACT CCT GCTTG-3'. The expected lengths of the amplified products for β-catenin and β-actin were 132 and 475 bp, respectively. The PCR was performed on a thermal cycler (Mastercycler Nexus; Eppendorf China, Ltd., Shanghai, China) under the following conditions: 94˚C for 2 min, followed by incubation at 94˚C for 45 sec, 55˚C for 45 sec and 72˚C for 45 sec, for a total of 32 cycles, and a final step at 72˚C for 5 min. The results were semiquantitatively analyzed using 3% agarose gel electrophoresis (Submarine Electrophoresis Unit; Hoefer™; Thermo Fisher Scientific, Inc.) and visualized using a digital gel documentation system (GelDoc 2000 System/QuantityOne software; Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Western blotting assay for the detection of siRNA efficiency on β-catenin protein expression. Four groups of SW480 cells (Blank control; negative control; liposome; transfected) were washed with phosphate-buffered saline (PBS) and lysed with lysis buffer (150 mmol/l NaCl, 50 mmol/l Tris, 1% sodium deoxycholate, 0.1% sodium dodecylsulfate, 1% Triton X-100, 5 mmol/l ethylene diaminetetra acetate; Shanghai Solarbio Bioscience & Technology Co., Ltd.) for 20 min on ice and then centrifuged (4,500 x g for 10 min). Protein levels were determined using the Pierce BCA Protein Assay (Pierce™; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Next, equal aliquots of the cell lysates were run on 10% sodium dodecyl sulfate-polyacrylamide gel and then electrotransferred onto polyvinylidene fluoride membranes (Shanghai Solarbio Bioscience & Technology Co., Ltd.), which were blocked with 5% skimmed milk powder dissolved in Tris-buffered saline with Tween ® 20 for 2 h at 4˚C. The membranes were incubated with polyclonal rabbit anti-β-catenin (catalog no. sc-7199) and mouse monoclonal anti-β-actin (catalog no. sc-47778) antibodies (dilution, 1:500; Santa Cruz Biotechnology Inc., Dallas, TX, USA) overnight at 4˚C, then with a secondary goat anti-rabbit IgG antibody (catalog no. G21079; 1:1,000; Invitrogen™; Thermo Fisher Scientific, Inc.) for 2 h at room temperature. Chemiluminescence (Shanghai Solarbio Bioscience & Technology Co., Ltd.) and optical density (OD) analysis were used to detect the expression levels of β-catenin. β-actin served as an internal reference.
E f f e c t o f s i R N A o n c e l l p r o l i f e r a t i o n b y 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay. SW480 cells on logarithmic growth phase were trypsinized (Shanghai Solarbio Bioscience & Technology Co., Ltd.) and seeded in 96-well plates (Shanghai Solarbio Bioscience & Technology Co., Ltd.) at a density of 5x10 3 cells/ml. Upon 24-h incubation, cells were transfected for 24, 48, 72 or 96 h. Next, 200 µl MTT solution was added, and incubation continued for additional 4 h. Subsequently, the cell supernatant was discarded, and 100 µl dimethyl sulfoxide (Shanghai Solarbio Bioscience & Technology Co., Ltd.) was added. Plates were gently rocked at room temperature for 15 min, and the OD at 570 nm was measured with a microplate reader (ELx800; BioTek, Winooski, VT, USA). A growth curve was generated by plotting the incubation time in the horizontal axis and the OD values is the vertical axis.
Flow cytometry for the detection of cell apoptosis. Apoptosis was detected using Annexin V/propidium iodide double staining (Shanghai Solarbio Bioscience & Technology Co., Ltd.). Cells in each group were collected, digested and resuspended in PBS. Flow cytometry (BD FACSCalibur™; BD Biosciences) was used to detect cell apoptosis, according the protocol provided by the manufacturer of the kit. In the flow cytometry plots, the lower left quadrant represented cell debris, while the lower and upper right quadrant represented early and late apoptotic cells, respectively. The upper left quadrant corresponded to dead cells. The apoptotic rate for each group was calculated as the average of three independent measurements, according to the following formula: Apoptosis rate (%) = (number of apoptotic cells/number of total cells) x 100.
Matrigel transmembrane invasion assay for the detection of cell invasiveness in siRNA-transfected SW480 cells. The Matrigel transmembrane invasion assay was performed in a Transwell plate (Corning, Inc., Corning, NY, USA). Complete medium was added to the upper chamber of Transwell plate pretreated with Matrigel (BD Biosciences), and complete medium containing 10% FBS was added to the lower chamber, following incubation for 1 h at 37˚C. The experimental and control groups were suspended at a cell density of 1x10 5 cells/ml, and 200 µl of these suspensions were transferred to the upper chamber, followed by incubation for 24 h. Subsequently, cells on the filter membranes were harvested, and the number of cells was counted under a microscope (IX71; Olympus Corporation, Tokyo, Japan).
Caspase-3 activity assay to detect the influence of siRNA on the caspase-3 activity in SW480 cells. Caspase-3 activity was measured using a kit (Shanghai GenePharma Co., Ltd.) that contained caspase-3 sequence-specific peptides conjugated to a chromophore. When the substrate was cleaved by caspase-3, the chromophoric group was released, which could be monitored by measuring the OD of the sample at a wavelength of 405 nm on a microplate reader, thus obtaining the relative activity of caspase-3. The experiments were conducted according to the manufacturer's protocol.
Statistical analysis. Statistical analysis was performed using SPSS version 17.0 software (SPSS Inc., Chicago, IL, USA). Data were expressed as the mean ± standard deviation. Student's t-test and one-way analysis of variance were used to compare the means across different groups. P<0.05 was considered to indicate a statistically significant difference.
Results
β-catenin-siRNA inhibits β-catenin messenger (m)RNA expression. The results presented in Fig. 1 indicate that, following β-catenin-siRNA transfection for 48 h, the relative mRNA expression levels of β-catenin in β-catenin-siRNA transfected SW480 cells were 0.044±0.003, while in the blank control, negative control and liposome groups, the relative mRNA expression levels of β-catenin were 0.465±0.063, 0.468±0.037 and 0.417±0.066, respectively. These results indicate that the expression of β-catenin was significantly reduced in the β-catenin-siRNA experimental group (P=0.004), compared with the blank control, negative control and liposome groups. No significant differences were observed among the blank control, negative control and liposome groups regarding the mRNA expression levels of β-catenin (P=0.611). Therefore, β-catenin-siRNA effectively inhibited the expression of the β-catenin gene in SW480 cells.
β-catenin siRNA inhibits the protein expression of β-catenin.
The results represented in Fig. 2 reveal that, following β-catenin-siRNA transfection for 48 h, the OD value of β-catenin protein expression in SW480 cells was 0.102±0.005, while in the blank control, negative control and liposome groups the OD values were 0.512±0.035, 0.519±0.047 and 0.566±0.036, respectively. Thus, in the transfected group, the protein expression levels of β-catenin were significantly lower than in the other groups (P=0.014). No significant differences were observed among the blank control, negative control and liposome groups in terms of β-catenin protein expression (P=0.237). Thus, β-catenin-siRNA effectively inhibited the protein expression of β-catenin in SW480 cells.
β-catenin-siRNA inhibits the proliferation of SW480 cells.
The results presented in Fig. 3 indicate that, following β-catenin-siRNA transfection for 24 h, there was no significant difference in SW480 cell proliferation in the β-catenin-siRNA-transfected group, compared with the blank control, negative control and liposome groups. However, upon 
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transfection for 48, 72 and 96 h, cell proliferation was significantly lower in the β-catenin-siRNA-transfected group than in the other groups (P=0.007). The blank control, negative control and liposome groups exhibited no significant differences in cell proliferation (P=0.255). Thus, β-catenin-siRNA-mediated silencing of β-catenin gene expression was able to inhibit the proliferation of SW480 cells.
β-catenin-siRNA influences the apoptosis of SW480 cells.
The results presented in Fig. 4 and Table I reveal that, upon silencing the β-catenin gene by β-catenin-siRNA, the apoptosis rate of SW480 cells was significantly higher in the β-catenin-siRNA-transfected group than in the blank control, negative control and liposome groups (18.76±2.79% vs. 5.22±1.13, 5.42±1.44 and 4.96±1.11%, respectively; P=0.004). There was no significant difference in apoptosis among the blank control, negative control and liposome groups (P=0.166). Thus, β-catenin-siRNA transfection inhibited the apoptosis of SW480 cells. Table I indicate that, following transfection with β-catenin-siRNA for 48 h, the levels of caspase-3 activity in the harvested SW480 cells were 0.15±0.02, 0.16±0.02, 0.16±0.03 and 0.48±0.05 OD value (P=0.005) in the blank control, negative control, liposome and β-catenin-siRNA-transfected groups, respectively. Thus, transfection with β-catenin-siRNA was able to increase caspase-3 activity in SW480 cells.
β-catenin-siRNA promotes the activation of caspase-3 in SW480 cells. The results in
Influence of β-catenin-siRNA on SW480 cell invasion and metastasis. The number of SW480 cells passing through the Matrigel membrane that was inhibited by transfection with β-catenin-siRNA indicated the invasion ability of SW480 cells in vitro. The results in Table II show that the in vitro invasiveness of SW480 cells transfected with β-catenin-siRNA for 24, 48 and 72 h, which were subsequently seeded into the invasion chamber and observed 24 h later, decreased following β-catenin-siRNA transfection (P=0.007), while no significant differences were observed among the different control groups (P=0.157). Following transfection with β-catenin-siRNA for 48 and 72 h, the number of cells infiltrating the membrane in the β-catenin-siRNA-transfected group was significantly reduced, compared with that in the other control groups (P=0.002), indicating that β-catenin-siRNA was able to reduce the invasiveness of SW480 cells in vitro in a time-dependent manner.
Discussion
Tumorigenesis, cancer progression and metastasis are complex processes (6) . In recent years, the association between catenin and cancer has become well known and the number of studies on the association between cell adhesion molecules and malignant behavior has increased (7, 8) . β-catenin is an important multifunctional cytoplasmic protein, which was initially considered as an intracellular molecule on the cell membrane that interacted with the calcium-dependent adhesion molecule E-cadherin (9) . However, the isolation and cloning of β-catenin enabled to identify its dual function as mediator of cell adhesion and participant in Wnt signaling (10) . β-catenin is located in the activation center of the Wnt signaling pathway, and is overexpressed in numerous tumors, including Transfection, cell number melanoma, leukemia, and small cell, breast and head and neck cancer (11) (12) (13) . β-catenin is closely associated with various factors involved in the formation of tumors, and participates in multiple aspects of tumor development (14) .
In the present study, siRNA technology was used, and double-stranded siRNA targeting β-catenin was synthesized (15) (16) (17) . The experimental results indicated that specific siRNA targeting β-catenin could inhibit the expression of the β-catenin gene. RT-PCR and western blotting results demonstrated that, following transfection with β-catenin-siRNA, the mRNA and protein expression levels of β-catenin appeared to be significantly decreased, suggesting that siRNA could effectively block the Wnt signaling pathway.
The present study used RNA interference technology to explore the impact of silencing the β-catenin gene on the biological behavior of SW480 cells, and observed that the chemically synthesized β-catenin-siRNA could effectively inhibit the expression of β-catenin in SW480 cells. When the expression of the β-catenin gene was suppressed, the proliferation of SW480 cells was inhibited, and the apoptosis rate increased in these cells, which may be explained by the inhibition of apoptosis and promotion of proliferation mediated by β-catenin in SW480 cells. Thus, when β-catenin expression was inhibited, the apoptosis rate of SW480 cells increased. The anti-apoptotic mechanism of β-catenin is not yet entirely clear, but it may involve caspase-3, which is a major effector caspase in downstream apoptotic signal transduction pathways (18) . In the present study, β-catenin-siRNA was used to inhibit β-catenin gene expression, which led to increased activity of caspase-3. Since β-catenin inhibits the apoptosis of SW480 cells and promotes their proliferation, the apoptosis of SW480 cells increases when the expression of β-catenin is disrupted. Studies on β-catenin and tumor invasiveness are limited. The present study has demonstrated that, upon silencing β-catenin gene expression, the number of SW480 cells penetrating the membrane in an invasion assay was significantly decreased, indicating that the invasive ability of these cells was significantly decreased. Thus, β-catenin-siRNA could effectively inhibit the expression of β-catenin in SW480 cells, and when β-catenin expression was suppressed, SW480 cell proliferation and invasion capacity were decreased, while apoptosis and caspase-3 activity were increased.
In the present study, SW480 cells with silenced β-catenin gene in the experimental group were characterized by slow proliferation in cell culture, low number of colonies formed in soft agar and markedly inhibited cell growth. Considering the experimental results obtained upon silencing the β-catenin gene and colon cancer cell proliferation, it is possible to speculate that in SW480 colon cancer cells specific siRNA targeting β-catenin may silence the β-catenin gene and sequentially silence its downstream genes. By silencing and inhibiting these upstream and downstream genes, the proliferation of SW480 cells was inhibited in vitro. Therefore, it can be proposed that, by interfering with the Wnt signaling pathway, β-catenin may act as a potential target gene for the treatment of colon cancer. However, further studies are required to guarantee that β-catenin-siRNA technology is stable, effective and secure to be used in clinical practice.
